Clinical trial for Non-small Cell Lung Cancer
Official title Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
ClinicalTrials.gov ID: NCT06343402
What this study is testing
What is BBO-8520?
BBO-8520 is an investigational medicine, taken by mouth, being studied as a potential treatment for non-small cell lung cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study checks if the new drug is safe and if it helps shrink tumors in people with advanced lung cancer.
- Who it's for
- Adults with non-small cell lung cancer that has spread or cannot be removed by surgery, and has a specific genetic change called KRAS G12C.
- What's involved
- Participants will take BBO-8520 alone or with other medicines, and undergo regular tests to check for side effects and tumor changes.
- Time commitment
- The study involves regular visits to the clinic for monitoring and testing over a period of time.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically documented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation
- Measurable disease by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
You likely can't join if
- Patients with malignancy within the last 2 years as specified in the protocol
- Patients with untreated or unstable brain metastases
- Patients with known hypersensitivity to BBO-8520 or its excipients
- Patients with a known hypersensitivity to pembrolizumab or its excipients
- Patients with active autoimmune disease of history of autoimmune disease that might recur
- Patients with a history of interstitial lung disease/pneumonitis that required steroids, or current interstitial lung disease/pneumonitis Other...
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- La Jolla, California, United States
- San Francisco, California, United States
- Santa Monica, California, United States
- Aurora, Colorado, United States
- New Haven, Connecticut, United States
- Norwalk, Connecticut, United States
- Peoria, Illinois, United States
- Kansas City, Kansas, United States
- Baltimore, Maryland, United States
- Detroit, Michigan, United States
- Buffalo, New York, United States
- New York, New York, United States
- Cleveland, Ohio, United States
- Eugene, Oregon, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- Waco, Texas, United States
- Salt Lake City, Utah, United States
- Fairfax, Virginia, United States
+ 16 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; La Jolla, California, United States; San Francisco, California, United States; Santa Monica, California, United States; Aurora, Colorado, United States; New Haven, Connecticut, United States and 30 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.